Whalesbook
Gland Pharma dwara 690,019 ESOPs da grant: Poori jaankari
Gland Pharma Limited ne apni ESOP Compensation Committee dwara 124 karmachariyan layi 690,019 Employee Stock Options (ESOPs) approve kitey han. Eh grant 'ESOP 2025' scheme da hissa hai.
Grant Details di jankari
Milaye gaye ESOPs ch, 455,413 options da exercise price ₹934.15 rakhiya gaya hai. Baaki 234,606 options da exercise price bahut kam, sirf ₹1 rakhiya gaya hai.
Eh options teen saalan vich vest honge: grant date (May 15, 2026) ton baad 34% pehle saal, 33% dooje saal, ate 33% tije saal vest honge. Vest hon ton baad karmachariyan kol apne options exercise karan layi 2 saal honge.
Raah de piche te Asar
Pharmaceutical sector vich ESOPs ek aam strategy hai taan jo khaas pratibha (talent) nu attract kita jaave, motivate kita jaave, ate company vich banaye rakheya jaave. Is grant da maksad karmachariyan de hita nu company di lambi kaal di performance ate shareholder value naal jodna hai.
Karmachariyan layi, eh options potential equity ownership da mauka dinde han, jihna naal zyada commitment ate productivity aundi hai. Par, is grant naal existing shareholders layi future dilution da khadsha v ho sakda hai, ate stock-based compensation costs da v asar company de kharchyan te pavega.
Company da Sandarbh
Gland Pharma global pharmaceutical industry vich ikk mahatvapurna company hai, jo injectables ate active pharmaceutical ingredients (APIs) vich apni maharat layi jaani jandi hai. Company pehlan vi stock options da istemal kar chuki hai, jivein ki ESOP 2020 scheme, jo employee incentives layi ikk lagatar approach darsaundi hai.
Mukhi Khatre
Sab ton bada khatra yeh hai ki options vest hon ton pehlan karmachari company chadh jaan, jihna naal retention da maksad poora nahi ho sakda. Vadi sankhya vich options exercise hunde han te existing shareholders layi significant dilution ho sakdi hai. ₹1 da low exercise price karmachariyan layi faydemand hai par company layi ikk vadda kharcha hai, jihde te nazar rakhni zaruri hai.
Industry Practice
Bahut sariyan badiyan Indian pharmaceutical companies, jinna vich Divi's Laboratories, Laurus Labs, ate Syngene International shamil han, ohan vi stock-based compensation strategies da istemal kardi han. Eh plans competitive industry vich scientific ate managerial talent nu attract ate retain karan layi bahut zaroori han.